New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer’s
Psychedelics R&D biotech Biomind Labs Inc.
Psyched: Musk’s Empathy Tweets, Psychedelics In Congress, Oregon’s Opt-Outs, MAPS’ MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Biomind Labs: Q3 Financials & FDA Approval For New Chemical Entity Targeting Treatment-Resistant Depression
Next-gen psychedelics developer Biomind Labs Inc.
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS:
GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96
LOSERS:
Psychedelic Stock Gainers And Losers From November 8, 2022
GAINERS:
Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
GAINERS:
Allied (OTC:ALID) shares closed up 4.10% at $0.44
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD).
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS:
Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS:
Allied (OTC:ALID) shares closed up 10.21% at $0.53
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS:
Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14